Dr. Bittar is the Director and General Manager of Cardiac Catheterization Laboratories and Cardiovascular Services at the Union Hospital System in Terre Haute, Indiana. Dr. Bittar is also the president of Providence Medical Group, a large multispecialty practice. He has more than 30 years of experience as an interventional cardiologist and is very active in clinical practice and medical education. Dr. Bittar is ABIM Board Certified in Cardiovascular Disease and Interventional Cardiology. He is also certified by the American Board of Vascular and Endovascular Medicine as well as by the National Lipid Association.

Before going into private practice, Dr. Bittar was a full-time academic faculty member at the State University of New York, Upstate Medical Center in Syracuse, New York. There, he was the Director of the Catheterization Lab at the VA Medical Center and was highly involved in teaching medical residents and cardiology fellows. He continues to teach medical students about cardiovascular medicine as clinical faculty at the Indiana University School of Medicine. He has a great interest in the interplay of different atherosclerosis risk factors—particularly lipids—and the development of vascular diseases.

Dr. Bittar attended medical school at Aleppo University School of Medicine in Syria. He then completed an internal medicine residency and cardiology fellowship at Brooklyn Hospital in New York. This was followed by a fellowship in interventional cardiology at Marshall University in Huntington, West Virginia. Later, he continued further interventional training at St. Vincent’s Medical Center in Indianapolis. In addition, he also completed a Master of Business Administration in Healthcare at George Washington University in Washington, D.C.

As of May 2025, Dr. Bittar reported no ongoing external relationships.

Dr. Alraies is the Medical Director of the Cardiac Catheterization Laboratory and Cardiac Rehabilitation Interventional Cardiology Research at Detroit Medical Center. Dr. Alraies’ clinical and research interests are focused on complex coronary interventions, mechanical circulatory support, medical education and digital media as learning tools for physicians. He has published more than 300 manuscripts in major peer-reviewed journals and several book chapters on the outcome of coronary interventions, mechanical circulatory support and transcatheter aortic valve replacement.

Dr. Alraies received a medical degree from the University of Aleppo in Syria. He completed internal medicine residency training at St. Vincent Charity Medical Center in Cleveland, followed by fellowship training in cardiology at the University of Minnesota and interventional cardiology at Detroit Medical Center/Wayne State University. He is ABIM Board Certified in Cardiovascular Disease and Interventional Cardiology.

As of September 2024, Dr. Alraies reported no ongoing external relationships.

Dr. Bansal is an interventional cardiologist and Vice President of Baltimore Heart Associates in Baltimore. He is ABIM Board Certified in Cardiovascular Disease and Interventional Cardiology and holds additional certification in nuclear cardiology and echocardiography. He is a fellow of the American College of Cardiology. Dr. Bansal is extensively involved in cardiology training and teaching of medical students and residents at Sinai Hospital of Baltimore, which is affiliated with both Johns Hopkins University and the George Washington School of Medicine. He has been voted "Top Doc of Baltimore" by Baltimore Magazine for multiple years. He has authored several peer-reviewed articles on topics of importance to the cardiology and interventional cardiology community. Previously, Dr. Bansal served on the ABIM Cardiovascular Disease Item-Writing Task Force.

Dr. Bansal received his medical degree from All India Institute of Medical Sciences in India, a premier institute consistently ranked number one in the country. He completed his interventional cardiology fellowship at Emory University in 2010.

As of September 2024, Dr. Bansal reported no ongoing external relationships.

Dr. Ephrem is a clinical and interventional adult congenital, coronary and structural heart diseases specialist. He is the Director of Structural Heart Interventions at the University of Tennessee Health Science Center/Lt. Col. Luke Weathers, Jr. VA Medical Center and an Assistant Professor of Medicine at the University of Tennessee Health Science Center. He is a fellow of the American College of Physicians, the American College of Cardiology and the Society for Cardiovascular Angiography and Interventions. He is ABIM Board Certified in Cardiovascular Disease, Interventional Cardiology and Adult Congenital Heart Disease; he is also board certified in echocardiography and nuclear cardiology.

Dr. Ephrem has received awards and peer recognition for his research. His main investigative interest is outcomes research in the adult congenital heart disease population, especially in the transition of proven therapies in the general patient population to the adult congenital population. He has published a series of articles, including many in the highest impact journals pertaining to this field, as well as innovative approaches in catheterization of cardiac patients in general, and the adult congenital population in particular. He also serves on the ABIM Cardiovascular Board.

Dr. Ephrem completed his internal medicine residency at the Icahn School of Medicine Mount Sinai/Mount Sinai Beth Israel and a fellowship in cardiology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, along with a chief resident year and a Master of Science in Clinical Research Methods. He completed fellowship in adult congenital heart disease at Emory University School of Medicine. He completed his interventional cardiology training at Corewell Health William Beaumont University Hospital and his structural and congenital interventional cardiology fellowship at the University of Toronto.

As of April 2025, Dr. Ephrem reported no ongoing external relationships.

Dr. Marmur is a Professor of Medicine and Director of the Cardiac Catheterization Laboratory at SUNY Downstate Medical Center in Brooklyn. He received funding from several organizations, including the Ontario Heart and Stroke Foundation, the Medical Research Council of Canada and the National Institutes of Health, to support his research in interventional cardiology at Mount Sinai Medical Center.

Dr. Marmur has trained hundreds of physicians and served on the editorial boards of The Journal of the American College of Cardiology, The Journal of Cardiovascular Revascularization Medicine and The Journal of Invasive Cardiology. His research initially focused on the vascular response to injury using various devices such as excimer lasers and directional coronary atherectomy. With a focus on coagulation, he has contributed significantly to the basic science literature on hemostasis and thrombosis in the setting of vascular injury. Dr. Marmur holds a patent for the biomarker TIMP [tissue inhibitor of metalloproteinase], which may predict future adverse events such as myocardial infarction and death. His work in gene therapy and genomics has contributed to using recombinant DNA and viral vector technologies in models of human arterial disease. Currently, Dr. Marmur is focused on the Downstate Cardiac Catheterization Laboratory GeneBank and Biorepository, a repository of molecular genetic, angiographic and historical data on patients who have undergone cardiac catheterization.

Dr. Marmur earned his medical degree from Laval University, completed his residency in internal medicine at McGill University and pursued a cardiology fellowship at the University of Toronto.

As of April 2025, Dr. Marmur reported no ongoing external relationships.

Dr. Angiolillo, who is ABIM Board Certified in Internal Medicine, Cardiovascular Disease and Interventional Cardiology, is a Professor of Medicine and serves as the Director of Cardiovascular Research, Director of the Interventional Cardiology Fellowship Program, and staff cardiologist and interventional cardiologist at the University of Florida Health System. He joined the University of Florida College of Medicine-Jacksonville in 2004.

Much of Dr. Angiolillo's professional career has been devoted to cardiovascular research in the field of interventional cardiology and acute coronary syndrome. His largest national and international recognition has been for his pivotal contributions in the field of thrombosis. He has performed seminal studies on platelet function and modulation of antiplatelet drug response, including genetic studies, for which he has received numerous national and international academic recognitions, including being named to Thomson Reuters’ 2014 and 2015 list of The World's Most Influential Scientific Minds. He has also been a key investigator in the clinical development of numerous novel antithrombotic agents. His success in obtaining extramural funding has allowed to him to develop one of the most active clinical research centers in the United States.

Dr. Angiolillo has authored more than 300 peer-reviewed articles and 30 book chapters, and he is the editor of his own textbook on antithrombotic medicine. He has also been invited to deliver numerous lectures across the globe. In addition to holding active membership in many cardiovascular societies in the Unites States and Europe, Dr. Angiolillo is on the editorial board of numerous cardiovascular journals and acts as a scientific reviewer for many major journals and extramural funding agencies, including the National Institutes of Health and other federal funding agencies in several European countries.

Dr. Angiolillo graduated summa cum laude from the Catholic University of the Sacred Heart Medical School in Rome, where he completed training in medicine and cardiology. He subsequently pursued training in interventional cardiology at the Complutense University of Madrid in Spain. He received his doctoral degree in cellular and molecular cardiology.

As of September 2024, Dr. Angiolillo reported the following external relationships:

Funding for clinical trial expenses and staff, paid to the University of Florida, from the following companies:

• Amgen, for a trial on the use of a PCSK9 inhibitor.
• AstraZeneca, for a trial on ticagrelor.
• Bayer, for a trial on the use of a low-dose novel oral anticoagulant.
• Chiesi, for a trial on cangrelor.
• CSL Behring, for trials on raising high-density lipoprotein cholesterol.
• Idorsia, for a trial on a new antiplatelet.
• Janssen, for a trial on rivaroxaban.

Service on a research-related expert panel or advisory board for the following companies, with compensation as listed:

• Amgen, advising on evolocumab, receiving reimbursement for travel and honoraria.
• AstraZeneca, advising on ticagrelor, receiving reimbursement for travel and honoraria.
• Bayer, advising on a new formulation of aspirin, receiving reimbursement for travel and honoraria.
• Boehringer Ingelheim, advising on dabigatran, receiving reimbursement for travel and honoraria
• Bristol-Myers Squibb, advising on apixaban, receiving reimbursement for travel and honoraria.
• Chiesi, receiving reimbursement for travel and honoraria.
• Faraday Technology, receiving reimbursement for travel and honoraria.
• Janssen, advising on rivaroxaban, receiving reimbursement for travel and honoraria.
• Novo Nordisk, receiving reimbursement for travel and honoraria.
• PhaseBio, receiving reimbursement for travel and honoraria.
• Pfizer, advising on apixaban, receiving reimbursement for travel and honoraria.
• Sanofi, advising on clopidogrel, receiving reimbursement for travel and honoraria.
• Vectura, receiving reimbursement for travel and honoraria. 

Dr. Bailey is a Distinguished Professor of Medicine and Radiology in the Janey and Dolph Briscoe Division of Cardiology at the University of Texas Health Science Center in San Antonio. He is ABIM Board Certified in Cardiovascular Disease and Interventional Cardiology. Dr. Bailey's clinical focus is interventional procedures to treat structural and valvular heart disease as well as vascular blockages. He currently has research laboratories that are investigating the effects of NOX subtypes in promoting cardiovascular disease and translational research in the field of nanotechnologies and nanosensors.

Dr. Bailey is a past president of the Society for Cardiovascular Angiography and Interventions (SCAI) and is currently the Editor-in-Chief of Catheterization and Cardiovascular Interventions (CCI Journal) and serves on the editorial board of JACC Intervention and The American Journal of Cardiology. He is a fellow of the American College of Physicians and the American College of Cardiology, and a master fellow of SCAI. He is a member of the Association of University Cardiologists, the Association of Cardiology Professors and the International Andreas Greuntzig Society.

Dr. Bailey received his undergraduate degree in biology from the University of Oregon and his medical degree from the University of Oregon Health Science Center. He completed his internship, internal medicine residency and cardiovascular fellowship at Fitzsimmons Army Medical Center in Aurora, Colorado.

As of April 2025, Dr. Bailey reported the following ongoing external relationships:

Service on data and safety monitoring boards for the following companies, with honoraria:

• Boston Scientific

Dr. Blankenship is a practicing interventional cardiologist at Geisinger Medical Center in Danville, Pennsylvania, Director of the Geisinger cardiology department and catheterization laboratories, and an Adjunct Professor of Medicine at Temple University Medical College. He is ABIM Board Certified in Internal Medicine, Cardiovascular Disease and Interventional Cardiology.

He represents the American College of Cardiology (ACC) to the American Medical Association Relative Value Update Committee and co-chairs the ACC Current Procedural Terminology/Relative Value Update Committee Task Force. Dr. Blankenship is immediate past president of the Society for Cardiovascular Angiography and Interventions and has co-authored over 200 scientific abstracts and publications.

Dr. Blankenship earned his medical degree from Cornell University Medical College in New York. He completed his internship, residency and cardiology fellowship at the University of Michigan. In 2014, he received his master's degree in healthcare management from the Harvard School of Public Health.

As of September 2024, Dr. Blankenship reported the following external relationships:

Post-marketing clinical research, with funding provided to Geisinger Medical Center, from the following companies:

• Zoll, national principal investigator for a study on supersaturated oxygen in anterior myocardial infarction.

Dr. Blankenship serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

• The American Medical Association, Relative Value Update Committee, member, receiving reimbursement for travel expenses.
• The United States Food and Drug Administration, consultant, receiving reimbursement for travel expenses and honoraria. 

Dr. Miller is Associate Professor of Medicine in the Division of Cardiology at the Johns Hopkins University and Hospital. Her position includes clinical care, fellow training, clinical research, mentoring and quality improvement at the Johns Hopkins Hospital and throughout the Johns Hopkins Health System, where she also serves as Director of the Vascular Cardiology Program and Director of the Quantitative Angiographic Imaging Laboratory. Dr. Miller is a full-time faculty member at Johns Hopkins University School of Medicine, and is ABIM Board Certified in Cardiovascular Disease and Interventional Cardiology.

She founded and is the Executive Director of the Maryland Academic Consortium of Percutaneous Coronary Intervention Appropriateness and Quality, an organization dedicated to professional improvement. She has served on numerous national committees including the American College of Cardiology (ACC) National Cardiovascular Data Registry (NCDR) Management Board, the ACC-NCDR Cath-PCI Leadership Committee and the American Heart Association Clinical Interventional Cardiovascular Care committees. She has served on national expert consensus-writing committees, including Expert Consensus Document for Cardiac Catheterization Laboratories and Expert Consensus Document for Coronary Computed Tomographic Angiography (CTA).

Dr. Miller has published extensively in the fields of general and interventional cardiology. She is an accomplished clinical investigator, including leading the pivotal international imaging trial of coronary CTA and conventional angiography. She is also a recognized physician educator, lecturing nationally. Her most recent endeavors have focused on interventional procedural quality improvement through collaborative peer review and quantitative measures.

Dr. Miller graduated cum laude with majors in both chemistry and biology from St. Olaf College in Northfield, Minnesota. She received her medical degree from the University of Minnesota Medical School. She trained in internal medicine and completed her fellowship training in cardiology and interventional cardiology at Duke University in Durham, North Carolina.

As of June 2025, Dr. Miller reported no ongoing external relationships.

Dr. Rab is a professor and interventional cardiologist at Emory University, where he is extensively involved in the training and teaching of general cardiology and interventional cardiology fellows. He is ABIM Board Certified in Internal Medicine, Cardiovascular Disease and Interventional Cardiology and is a fellow of the American College of Cardiology and the Society of Cardiovascular Angiography and Interventions.

Dr. Rab currently serves on the Publications Committee and the Leadership Committee of the Interventional Section Leadership Council of the American College of Cardiology, where he is the chair of the complex angioplasty group. He was the former chair of the Interventional Section's publication committee, having authored or coauthored twelve peer reviewed articles on topics of importance to the interventional community.

Dr. Rab received his medical degree from the University of Karachi in Pakistan. He completed residency training in internal medicine at the Henry Ford Hospital in Detroit and trained at Emory University in cardiology and interventional cardiology.

As of May 2025, Dr. Rab reported the following ongoing external relationships:

Dr. Rab serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

• The American College of Cardiology, committee member, without compensation.
• The Society for Cardiovascular Angiography and Interventions, member and host of monthly webinars, receiving honoraria.